

### **JCHS-CQ-01-2023**

### **Hypercoagulability in Severe COVID Infection**

Mohammed Fauzi Abdul Rani

Department of Internal Medicine, Faculty of Medicine, Universiti Teknologi MARA(UiTM), Sungai Buloh, Selangor, Malaysia

### **ANSWER TO JCHS-CQ-01-2023**

#### **Question 1**

New pulmonary embolism in the visualised right lower lobe pulmonary arterial branch.

#### **Question 2**

Infection with COVID-19 may have heightened the patient's coagulability state for a protracted time resulting in recurrent pulmonary embolism or post-infection states (such as reduced mobility) have increased the overall venous thromboembolic (VTE) risks.

#### **Question 3**

The duration for anticoagulation should be extended for at least another 3 months.

#### **Discussion**

Nowadays clinicians are well aware that COVID-19 patients are at high risk of getting both pulmonary embolism (PE) and organizing pneumonia during the course of the acute infection with the incidence of both conditions increases with increasing category of the disease [1]. When a pulmonary embolism is confirmed by an imaging test such as computed tomography pulmonary angiogram, the recommended treatment by most guidelines is an anticoagulation therapy for at least 3 months [2]. In one case series looking at the fate of the pulmonary artery pressure post anticoagulation therapy, none developed detectable pulmonary hypertension when measured at 3 months despite about 30% had residual thrombosis of the affected vessel [3]. The presence of the residual thrombosis also had no impact on exercise tolerance of these patients [4] and it was not indicative of the risk of new or extension of the further pulmonary embolism [5].

In this case, the initial suspicion of the presence of a pulmonary vascular condition was the detection of the reduced transfer factor with normal static lung volume, which can be seen in chronic pulmonary embolism [6]. It can also be due to the underlying diffuse parenchymal lung disease. A new pulmonary embolism at 3 months was found despite compliance to anticoagulation therapy. Additional factors for pulmonary embolism such as history of long-distance travel, immobilisation, surgery, other medications, coagulation disorders or previous cancer were excluded at clinic review.

For patients on anticoagulation therapy, the most common reason for failure of treatment resulting in new clots is inadequate anticoagulation [7]. Inadequate anticoagulation often results from suboptimal or subtherapeutic treatment. However, through definite history of treatment compliance and the use of new anticoagulation, this was not the case for our patient.



The most serious long-term complication of PE is chronic thromboembolic pulmonary hypertension (CTEPH) but the data and clinical recommendation on how to risk stratify and investigate CTEPH in post COVID-19 patients is lacking [8]. In cases of PE from other causes, the recommendation for the assessment of CTEPH as a possible long-term complication is done at 3 months which coincides with the follow up timing of our patient. As done in our case report, echocardiogram is the preferred initial test to confirm the presence of pulmonary hypertension. To ascribe CTEPH as the cause, a ventilation perfusion scan is required to confirm that diagnosis [9]. Otherwise, an alternative explanation should be sought [10].

The pulmonary artery pressure measured during echocardiography in our patient was borderline and relatively unremarkable. The cause of reduced percentage of gas transfer was likely to be the new PE which warranted an additional period of anticoagulation of 3 months [11] In addition, a repeat investigation for hypercoagulable risk factors is necessary.

In conclusion, it is possible that the risk for recurrent VTE is enhanced in a selected group of post COVID-19 patients despite treatment with anticoagulation for 3 months. In our patient, continuing anticoagulation therapy beyond 3-month duration is therefore a very reasonable approach in unexplained new PE as we seek to understand more of the sequelae of infection from COVID-19. Large studies are needed to confirm this risk.

### Learning Points

- Pulmonary embolism is common during acute COVID-19 infection and may recur after the acute episode in absence of symptoms
- When there is persistent dyspnoea or hypoxaemia, a new pulmonary embolism must be considered an aetiology
- The recommended practice for post COVID-19 care is constantly evolving

### Conflict of Interest

Authors declare none.

### REFERENCES

1. Fang C, Garzillo G, Batohi B, Teo JT, Berovic M, Sidhu PS, Robbie H. Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease. *Clinical radiology*. 2020;75(10):780-8.
2. Valle C, Bonaffini PA, Dal Corso M, Mercanzin E, Franco PN, Sonzogni A, Vacca G, Gianatti A, Sironi S. Association between pulmonary embolism and COVID-19 severe pneumonia: Experience from two centers in the core of the infection Italian peak. *European Journal of radiology*. 2021; 137:109613.
3. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, Le Gal G, Rali P, Wells P. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. *Chest*. 2020; 158(3):1143-63.
4. Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, Dager WE, Deitelzweig SB, Ellsworth S, Garcia D, Kaatz S. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. *Journal of thrombosis and thrombolysis*. 2020; 50:72-81.
5. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, Levi M, Samama CM, Thachil J, Giannis D, Douketis JD. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. *Journal of Thrombosis and Haemostasis*. 2020; 18(8):1859-65.
6. Whyte MB, Barker R, Kelly PA, Gonzalez E, Czuprynska J, Patel RK, Rea C, Perrin F, Waller M, Jolley C, Arya R. Three-month follow-up of pulmonary embolism in patients with COVID-19. *Thrombosis Research*. 2021; 201:113-5.

7. Ma KA, Kahn SR, Akaberi A, Dennie C, Rush C, Granton JT, Anderson D, Wells PS, Rodger MA, Solymoss S, Kovacs MJ. Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: results of the ELOPE Study. *Research and Practice in Thrombosis and Haemostasis*. 2018; 2(4):670-7.
8. den Exter PL, van Es J, Kroft LJ, Erkens PM, Douma RA, Mos IC, Jonkers G, Hovens MM, Durian MF, ten Cate H, Beenen LF. Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism. *Thrombosis and haemostasis*. 2015; 114(07):26-34.
9. George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, Gibbons MA, Hart N, Jenkins RG, McAuley DF, Patel BV. Respiratory follow-up of patients with COVID-19 pneumonia. *Thorax*. 2020; 75(11):1009-16.
10. Tapon VF, Hockberger RS. Treatment, prognosis, and follow-up of acute pulmonary embolism in adults. *UpToDate Walth. MA Consult*. 2017.
11. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *European heart journal*. 2020; 41(4):543-603.
12. Klok FA, Surie S, Kempf T, Eikenboom J, Van Straalen JP, Van Kralingen KW, Van Dijk AP, Vliegen HW, Bresser P, Wollert KC, Huisman MV. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. *Thrombosis research*. 2011; 128(1):21-6.
13. Klok FA, Tesche C, Rappold L, Dellas C, Hasenfuß G, Huisman MV, Konstantinides S, Lankeit M. External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. *Thrombosis research*. 2015; 135(5):796-801.
14. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, Kim NH, Humbert M, Jais X, Noordegraaf AV. ERS statement on chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*. 2021; 57(6).
15. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Sanchez MAG, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *European Respiratory Journal* 2015;46: 1855-1856. DOI: 10.1183/13993003.51032-2015
16. Kim NH, Delcroix M, Jenkins DP, Channick R, Darteville P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E. Chronic thromboembolic pulmonary hypertension. *Journal of the American College of Cardiology*. 2013; 62(25S): D92-9.

**Corresponding author:**

**Prof. Dr. Mohammed Fauzi Abdul Rani,**  
 Department of Internal Medicine,  
 Faculty of Medicine,  
 Universiti Teknologi MARA (UiTM),  
 Jalan Hospital, 47000 Sungai Buloh,  
 Selangor, Malaysia.  
 Email: mohammedfauzi@uitm.edu.my

**Received**

16<sup>th</sup> July 2021

**Received in revised form**

3<sup>rd</sup> January 2022

**Accepted**

26<sup>th</sup> March 2022

**Published**

1<sup>st</sup> March 2023